Consensus Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Real-time Estimate Cboe BZX 11:14:42 2024-03-28 am EDT 5-day change 1st Jan Change
5.14 USD +4.90% Intraday chart for Black Diamond Therapeutics, Inc. -4.99% +82.92%

Evolution of the average Target Price on Black Diamond Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0e0c71b53efa82.rRfGAF5Sj8ig_fKx9hnSNeCmXBdSIluUqn2eUBzODyM.2na-Rwdr6YHxvITzo3yFXqKSGHolVA3_hzusOk2WeVfHYq5xayXc_f_PlQ~dd7398e25f6713e6a65fb8df2979a310
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3 MT
Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating MT
Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating MT
Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22 MT
HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy MT
Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating MT
BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target MT
BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating MT
BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating MT
BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48 MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48 MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating MT
BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target MT
BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.9 USD
Average target price
10.6 USD
Spread / Average Target
+116.33%
High Price Target
12 USD
Spread / Highest target
+144.90%
Low Price Target
10 USD
Spread / Lowest Target
+104.08%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Black Diamond Therapeutics, Inc.

Piper Sandler
Stifel Nicolaus
HC Wainwright
Wedbush
Berenberg Bank
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Black Diamond Therapeutics, Inc. - Nasdaq
  4. Consensus Black Diamond Therapeutics, Inc.